Wednesday, April 15, 2026
The cell therapy sector remains constrained by particulate guidance based on traditional parenteral products, says a BioPhorum publication.
In theory, in vivo makes other cell therapies obsolete, but a panel at BPI Europe in Vienna last month painted a more measured picture.